Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA extends review of Pfizer's Fablyn until January

This article was originally published in Scrip

Executive Summary

The US FDAhas extended the review period for Pfizer's selective oestrogen receptor modulator (SERM), Fablyn (lasofoxifene), by three months until January to analyse complete five-year data from the pivotal PEARL study, the company said. In September an advisory panel endorsed approval of Fablyn for the treatment of osteoporosis in women. Committee members generally recommended the SERM for second-line use owing to safety issues raised during clinical trials, including increases in all-cause mortality, thromboembolic events and gynaecological problems. At the time of the meeting preliminary five-year data from the 8,556-patient, placebo-controlled PEARL study were available, but a final report had not been submitted to the agency. The FDA concluded that three-year PEARL data demonstrated lasofoxifene was effective in significantly reducing the risk of new or worsening radiographic vertebral fractures.

You may also be interested in...

US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.

Mallinckrodt’s Hepatorenal Syndrome Drug Terlipressin Gets A Virtual AdComm

US FDA cardiovascular and renal drugs panel will weigh approvability of the vasopressin analog during a nine-hour, online meeting 15 July; terlipressin was the focus of a 2009 complete response letter but met its primary endpoint in the recent CONFIRM trial.

Informed Consent: For COVID-Affected Studies, A Handwritten Document May Suffice

Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol, and texting or emailing a photo of the signed document to the investigator, the US FDA says in its latest guidance update.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts